We are a medtech company dedicated to developing innovative solutions with the potential to transform precision diagnosis and treatment of cardiovascular diseases.

As a leading player in the interventional cardiovascular device market, we have developed the first and only domestic fractional flow reserve (FFR) system approved by the NMPA in China.Our FFR system also obtained the CE Mark in March 2020.

Additionally, our 1st Generation Intravascular Ultrasound (IVUS) system was the first domestic IVUS system to have entered into clinical trials and completed patient enrollment in China. With our FFR and IVUS products, we are the only domestic medical device company in China with a product portfolio in both precision intravascular physiology and imaging. 

Since our inception, we have focused on developing innovative technologies to precisionize the care of cardiovascular diseases, with a vision to build a world-class medical technology company of long-lasting impact.

Led by our strong management team, and leveraging our proprietary technologies, deep industry insights, and extensive experience in research and development, we have developed a total solutions platform for the precision diagnosis and treatment of major cardiovascular diseases, including coronary artery disease, atrial fibrillation, and peripheral artery disease.

We have built a synergistic platform that seamlessly integrates our R&D, manufacturing and commercialization capabilities, thus enhancing collaboration across different functions, accelerating product development, achieving cost-efficiency and promoting innovation.

We industriously and consistently pursue our mission to transform healthcare through innovation and quality.